Navigation Links
OREXIGEN Therapeutics Announces Sustained-Release Formulation of,Zonisamide Shows Improved Tolerability When Compared to Immediate,Release Formulation

orexigen.com/">http://www.orexigen.com.

Forward-Looking Statements

Orexigen cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved. For example, statements regarding the potential progress and results of clinical trials and the use of funds to support such trials may be forward looking statements. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Orexigen's business, including, without limitation: Orexigen's clinical trials may not proceed in the timeframes or in the manner Orexigen expects or at all; the results of earlier clinical trials may not be predictive of future results; the scientific theories relating to the central nervous system on which Orexigen has based its development programs may not result in product candidates with sufficient efficacy or safety to obtain regulatory approval or commercial success; Orexigen and its licensors may not be able to obtain, maintain and successfully enforce adequate patent and other intellectual property protection of its product candidates; and other risks detailed in Orexigen's public filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Orexigen undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

     CONTACTS:

     Graham Cooper         Media:                        Investors:

     Orexigen CFO 
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
(Date:7/22/2014)... 22, 2014  Pressure BioSciences, Inc. (OTCQB: ... Genomics ("Parabase"), (together "the companies"), today announced ... and development agreement (the "collaboration"). Under the ... a front-end, sample preparation method for Parabase,s ... testing process. The sample preparation method will ...
(Date:7/22/2014)... OXFORD, England , July 22, 2014 /PRNewswire/ ... pharmaceutical development and device company focused on solid ... that its novel solid formulation of octreotide acetate ... comparing it with the currently marketed liquid product ... to transfer the formulation production process to a ...
(Date:7/21/2014)... Companies that supply Durable Medical Equipment, ... consumers directly about purchasing such supplies even if ... American Osteopathic Association,s House of Delegates voted to ... that supply Durable Medical Equipment unless such equipment ... and the patient. Typically Durable ...
Breaking Medicine Technology:Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform 2Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform 3Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform 4Glide Pharma Completes Successful Proof-of-Concept Study with Novel Solid Dose Formulation of Octreotide 2American Osteopathic Association Calls for Eliminating Unsolicited Requests to Purchase Medical Equipment 2
(Date:7/22/2014)... (PRWEB) July 22, 2014 Thought ... a set of simple tools, designed to help clinicians ... little or no experience with biofeedback. The tools in ... situations and elucidate any abnormal patterns to teach them ... fast paced world, we are familiar with stress and ...
(Date:7/22/2014)... telephone numbers to foreign vocabulary, our brains hold ... we are getting older, our ability to learn ... scientists around Associate Prof Dr Antonio Del Sol ... of the University of Luxembourg and Dr Ronald ... identified the molecular mechanisms of this cognitive decline ...
(Date:7/22/2014)... 2014 There’s an old adage that ... the new improvements and enhancements Global Eyeglasses has made, ... make lasting impressions while having what they need to ... everyday. , “We are offering new sports clip prescription ... Arjun Sagar, CEO of Global Eyeglasses . ...
(Date:7/22/2014)... Transparency Market Research has announced the addition ... Market – Global Industry Analysis, Size, Share, Growth, Trends ... database. This industry is considered as the most well-established ... at USD 8.7 billion by 2019 and expected to ... 2019. Molecular diagnostics is the class of diagnostic test ...
(Date:7/22/2014)... Brand journalism tactics for ... Ragan Communications 2014 Health Care PR and Marketing ... consecutive year that MediaSource placed in the finalist category ... the winning MediaSource team last year. This year the ... against three other contenders that include AMF Media Group ...
Breaking Medicine News(10 mins):Health News:Thought Technology to Present Software for Stress Control at the 2014 American Psychological Association Convention in DC 2Health News:Thought Technology to Present Software for Stress Control at the 2014 American Psychological Association Convention in DC 3Health News:Rigid connections: Molecular basis of age-related memory loss explained 2Health News:Global Eyeglasses Adds New Products and Enhances Services 2Health News:Global Molecular Diagnostics Market Expected to Reach USD 8.7 Billion through 2019: Transparency Market Research 2Health News:Global Molecular Diagnostics Market Expected to Reach USD 8.7 Billion through 2019: Transparency Market Research 3Health News:Global Molecular Diagnostics Market Expected to Reach USD 8.7 Billion through 2019: Transparency Market Research 4Health News:MediaSource Brand Journalism Returns to Best Health Care Agency Competition in Ragan Communications Health Care Awards 2Health News:MediaSource Brand Journalism Returns to Best Health Care Agency Competition in Ragan Communications Health Care Awards 3
... of Helsinki have found a mechanism in the memory centre ... the information processing required later in life. The study was ... Journal of Neuroscience. The brain cells in the ... the middle of chaos, they are looking for contact with ...
... , FRIDAY, May 14 (HealthDay News) -- Babies born with ... a higher risk for infant death, brain damage and/or childhood ... finding, reported online May 14 in BMJ , stems ... Hospital in England. , The authors note that when a ...
... guidelines help patients, doctors decide on removal to avoid unnecessary ... no guidelines existed for one of the more difficult ... device, such as an implanted defibrillator, in a patient,s final ... life-saving electric shock to restart a heart that stops ...
... ... Announces Plans to Franchise Medical Marijuana Dispensaries in CA, Stock is ... are planning to franchise medical marijuana dispensaries compliant with state and ... (500%) in two days. For more complete coverage on the ...
... ... and fresh water aquatic fish habitats. With composition similar to natural rock formations, ... , ... York (PRWEB) May 14, 2010 -- CerMedia announced today at Interzoo 2010 in Nürnberg, ...
... ... the planning of a new retail and consumer hub for the region is starting to draw ... ... Costa Rica real estate continues to thrive on the South Pacific coast, the planning of ...
Cached Medicine News:Health News:New information on the development of the brain 2Health News:Low Umbilical Cord pH Tied to Death, Brain Damage 2Health News:As End of Life Nears, What to Do With Implanted Defibrillators? 2Health News:As End of Life Nears, What to Do With Implanted Defibrillators? 3Health News:Cannabis Medical Solutions Announces Plan to Franchise Ownership of Medical Marijuana Dispensaries in California 2Health News:Cannabis Medical Solutions Announces Plan to Franchise Ownership of Medical Marijuana Dispensaries in California 3Health News:CerMedia Releases MarinePure High Surface Area Media for Aquatic Biofiltration 2Health News:Commercial Center to Cater to Costa Rica's South Pacific Coast 2Health News:Commercial Center to Cater to Costa Rica's South Pacific Coast 3
HME w/CO2 Sampling Port 22mm od/15mm od...
Indications For Usage: ,Infant (recommended tidal volume 20-70ml), single patient use on anesthetized patients and respiratory care patients who require a breathing circuit. The product is intended ...
Indications For Usage: ,Adult (recommended tidal volume >150ml), single patient use on anesthetized patients and respiratory care patients who require a breathing circuit. The product is intended to...
... The Portex® Thermovent® T helps provide protection ... It is small and extremely lightweight making it ... adults. With a high rate of heat and ... secretion retention., ,All HMEs and filters have ...
Medicine Products: